Sotio's DCVAC/OvCa improves survival in Phase II for recurrent ovarian cancer

Sotio reported March 19 that DCVAC/OvCa as second-line treatment decreased the risk of death by 62% in the Phase II SOV02 trial to treat recurrent, platinum-sensitive epithelial ovarian cancer.

DCVAC/OvCa is an active cellular immunotherapy for ovarian cancer that uses a patient's dendritic cells to induce an immune reaction against presented tumor antigens...